Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa
Novavax ' Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: African Health | Children | Clinical Trials | Malaria | Malaria Vaccine | Oxford University | Pharmaceuticals | Study | Vaccines